Mini-Series Title: “Nuclear Receptors in Ocular Health and Disease: Therapeutic Horizons from Cornea to Retina” Title: “Nuclear Receptors: The Eye’s Hidden Gatekeepers of Inflammation,Lipids,and Repair” Part 1: Setting the Stage
Restricted accessEditorialFirst published online May, 2026
Mini-Series Title: “Nuclear Receptors in Ocular Health and Disease: Therapeutic Horizons from Cornea to Retina” Title: “Nuclear Receptors: The Eye’s Hidden Gatekeepers of Inflammation,Lipids,and Repair” Part 1: Setting the Stage
JinP, DuanX, HuangZ, et al.Nuclear receptors in health and disease: Signaling pathways, biological functions and pharmaceutical interventions. Signal Transduct Target Ther, 2025; 10(1):228; doi: 10.1038/s41392-025-02270-3
2.
ChoudharyM, MalekG. Potential therapeutic targets for age-related macular degeneration: The nuclear option. Prog Retin Eye Res, 2023; 94:101130; doi: 10.1016/j.preteyeres.2022.101130
3.
TrevinoLS, GorelickDA. The interface of nuclear and membrane steroid signaling. Endocrinology, 2021; 162(8); doi: 10.1210/endocr/bqab107
4.
DixonED, NardoAD, ClaudelT, et al.The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity, diabetes and NAFLD. Genes (Basel), 2021; 12(5):645; doi: 10.3390/genes12050645
5.
de AlmeidaNR, Conda-SheridanM. A review of the molecular design and biological activities of RXR agonists. Med Res Rev, 2019; 39(4):1372–1397; doi: 10.1002/med.21578
6.
RehoB, FadelL, BrazdaP, et al.Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding. J Biol Chem, 2023; 299(2):102896; doi: 10.1016/j.jbc.2023.102896
7.
SafeS, OanyAR, TsuiWN, et al.Orphan nuclear receptor transcription factors as drug targets. Transcription, 2025; 16(2–3):224–260; doi: 10.1080/21541264.2025.2521766
8.
Nuclear Receptors Nomenclature C. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999; 97(2):161–163; doi: 10.1016/s0092-8674(00)80726-6
9.
LesovayaEA, ChudakovaD, BaidaG, et al.The long winding road to the safer glucocorticoid receptor (GR) targeting therapies. Oncotarget, 2022; 13:408–424; doi: 10.18632/oncotarget.28191
10.
XieZ, XinJ, HuangC, et al.Drugs targeting peroxisome proliferator-activated receptors. Drug Discov Today, 2025; 30(3):104318; doi: 10.1016/j.drudis.2025.104318
11.
LiY, ZhaoP, JiangB, et al.Modulation of the vitamin D/vitamin D receptor system in osteoporosis pathogenesis: Insights and therapeutic approaches. J Orthop Surg Res, 2023; 18(1):860; doi: 10.1186/s13018-023-04320-4
12.
LuczakJW, PalusinskaM, Maslinska-GromadkaK, et al.The next generation of skin care: Transforming retinoid therapeutics. Cells, 2025; 14(21); doi: 10.3390/cells14211650
RatziuV, ScanlanTS, BruinstroopE. Thyroid hormone receptor-beta analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol, 2025; 82(2):375–387; doi: 10.1016/j.jhep.2024.10.018
15.
KimN, LukongKE. Treating ER-positive breast cancer: A review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncol Rev, 2025; 19:1564642; doi: 10.3389/or.2025.1564642
16.
EscandonP, VasiniB, WhelchelAE, et al.The role of peroxisome proliferator-activated receptors in healthy and diseased eyes. Exp Eye Res, 2021; 208:108617; doi: 10.1016/j.exer.2021.108617
17.
MatlockHG, QiuF, MalechkaV, et al.Pathogenic role of PPARalpha downregulation in corneal nerve degeneration and impaired corneal sensitivity in diabetes. Diabetes, 2020; 69(6):1279–1291; doi: 10.2337/db19-0898
18.
SerpenJY, ArmentiST, PrasovL. Immunogenetics of the ocular anterior segment: Lessons from inherited disorders. J Ophthalmol, 2021; 2021:6691291; doi: 10.1155/2021/6691291
19.
RobertiG, OddoneF, AgnifiliL, et al.Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol, 2020; 65(4):458–472; doi: 10.1016/j.survophthal.2020.01.002
20.
HuY, ChenY, DingL, et al.Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A, 2013; 110(38):15401–15406; doi: 10.1073/pnas.1307211110
21.
JiaL, OhEC, NgL, et al.Retinoid-related orphan nuclear receptor RORbeta is an early-acting factor in rod photoreceptor development. Proc Natl Acad Sci U S A, 2009; 106(41):17534–17539; doi: 10.1073/pnas.0902425106
22.
KobayashiM, TakezawaS, HaraK, et al.Identification of a photoreceptor cell-specific nuclear receptor. Proc Natl Acad Sci U S A, 1999; 96(9):4814–4819; doi: 10.1073/pnas.96.9.4814
23.
OnishiA, PengGH, PothEM, et al.The orphan nuclear hormone receptor ERRbeta controls rod photoreceptor survival. Proc Natl Acad Sci U S A, 2010; 107(25):11579–11584; doi: 10.1073/pnas.1000102107
24.
ZhangCL, ZouY, YuRT, et al.Nuclear receptor TLX prevents retinal dystrophy and recruits the corepressor atrophin1. Genes Dev, 2006; 20(10):1308–1320; doi: 10.1101/gad.1413606
25.
Ayala-PenaVB, PilottiF, VolonteY, et al.Protective effects of retinoid x receptors on retina pigment epithelium cells. Biochim Biophys Acta, 2016; 1863(6):1134–1145; doi: 10.1016/j.bbamcr.2016.02.010
26.
ChoudharyM, DingJD, QiX, et al.PPARbeta/delta selectively regulates phenotypic features of age-related macular degeneration. Aging (Albany NY), 2016; 8(9):1952–1978; doi: 10.18632/aging.101031
27.
ChoudharyM, IsmailEN, YaoPL, et al.LXRs regulate features of age-related macular degeneration and may be a potential therapeutic target. JCI Insight, 2020; 5(1):e131928; doi: 10.1172/jci.insight.131928
28.
DwyerMA, KazminD, HuP, et al.Research resource: Nuclear receptor atlas of human retinal pigment epithelial cells: Potential relevance to age-related macular degeneration. Mol Endocrinol, 2011; 25(2):360–372; doi: 10.1210/me.2010-0392
29.
YaoPL, ParmarVM, ChoudharyM, et al.NURR1 expression regulates retinal pigment epithelial-mesenchymal transition and age-related macular degeneration phenotypes. Proc Natl Acad Sci U S A, 2022; 119(28):e2202256119; doi: 10.1073/pnas.2202256119
30.
Behar-CohenF, ZhaoM. Mineralocorticoid pathway in retinal health and diseases. Br J Pharmacol, 2022; 179(13):3190–3204; doi: 10.1111/bph.15770
31.
BrinksJ, van DijkEHC, KielbasaSM, et al.The cortisol response of male and female choroidal endothelial cells: Implications for central serous chorioretinopathy. J Clin Endocrinol Metab, 2022; 107(2):512–524; doi: 10.1210/clinem/dgab670
32.
MerriganSL, KennedyBN. Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF. Br J Pharmacol, 2017; 174(16):2636–2651; doi: 10.1111/bph.13875
